Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enbrel for Nail Psoriasis Monitored by OCT
NCT05135312Phase 4Unknown
- Sponsor
- OptiSkin Medical
- Start
- Aug 2021
- Primary completion
- Aug 2022
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 4, open-label trial of etanercept in psoriasis, psoriatic arthritis (PsA) and nail psoriasis, sponsored by OptiSkin Medical. Primary endpoints: Nail Psoriasis Severity Index at 24 weeks and Optical Coherence Tomography (clinical) at 24 weeks. Status: unknown.
02
Drugs
etanercept
03
Conditions
psoriasispsoriatic arthritis (PsA)nail psoriasis
Beyond the preview
Go deeper on NCT05135312.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05135312.